Viking Therapeutics, Inc.

Metabolic-disease biotech developing dual GLP-1/GIP agonist VK2735 in Phase 3 obesity development.

Back to company catalog

Obesity & metabolic disease · Peptide receptor agonists & small molecules · Phase 3

Compare report options